Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00286325 · ClinicalTrials.gov registry record · Phase 1
Rituximab in the Treatment of Patients With Bullous Pemphigoid
A Phase 1 study of Bullous Pemphigoid, sponsored by Duke University.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT00286325: Completed Phase 1 study of Bullous Pemphigoid, sponsored by Duke University.
NCT00286325 is a Phase 1 study of Bullous Pemphigoid that has completed, run by Duke University. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00286325, a Phase 1 study of Bullous Pemphigoid, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will determine the safety of treatment of bullous pemphigoid in patients resistant to therapy with systemic corticosteroids, with rituximab plus systemic corticosteroids.
Primary Outcome
The primary safety endpoint is the occurrence of treatment emergent adverse events including infections, infusion reactions and disease progression. These were determined by clinical evaluation and laboratory questions. Disease progression is defined as development of new blisters despite therapy. These are reported as the number of participants with a study related SAE.
Conditions Studied
Interventions
- DRUG Rituximab
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2005-03 |
| Est. Completion | 2010-03 |
| Phase | Phase 1 |
What the finished NCT00286325 record still lists
NCT00286325 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Bullous Pemphigoid appearing as the primary indexed condition, and to 1 intervention - of which Rituximab is the first listed.
NCT00286325 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT00286325 about?
NCT00286325 is a clinical study titled "Rituximab in the Treatment of Patients With Bullous Pemphigoid". This study will determine the safety of treatment of bullous pemphigoid in patients resistant to therapy with systemic corticosteroids, with rituximab plus systemic corticosteroids.
What is the current status of trial NCT00286325?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2005-03. Estimated completion is 2010-03.
What conditions does trial NCT00286325 study?
This clinical trial studies the following conditions: Bullous Pemphigoid.
What interventions are being tested in trial NCT00286325?
The interventions under investigation include: Rituximab (DRUG).
Who is sponsoring clinical trial NCT00286325?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00286325 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bullous Pemphigoid
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00286325's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia